Iveda Prices $2M Offering: 5.7M Shares and 11.4M Warrants at $0.35
Iveda priced a public offering of 5,714,286 common shares (or pre-funded warrants) plus series X warrants to buy 11,428,572 shares at $0.35 each, raising about $2.0 million in gross proceeds. Proceeds will fund R&D, debt repayment, working capital, capital expenditures, acquisitions and potential stock repurchases.
1. Offering Details
Iveda announced the pricing of a public offering consisting of 5,714,286 shares of common stock (or pre-funded warrants) and series X warrants to purchase up to 11,428,572 common shares, each unit priced at $0.35, resulting in gross proceeds of approximately $2.0 million.
2. Use of Proceeds
The company intends to apply net proceeds toward research and development projects, repayment of existing indebtedness, working capital needs, capital expenditures, acquisitions, joint ventures, and potential stock repurchase programs.
3. Warrant Terms
Series X warrants will be exercisable immediately at an exercise price of $0.35 per share and will expire two years from issuance, providing a leverage mechanism for future capital if warrant holders choose to convert.
4. Placement Agent and Registration
H.C. Wainwright & Co. is serving as exclusive placement agent, and the registration statement on Form S-1 was declared effective by the SEC on February 9, 2026, with closing expected on or about February 11 subject to customary conditions.